Medicare's prescription drug program : competition issues and cost trends / Gloria R. Pattinson, editor.

Format:

Book

Contributor:

Pattinson, Gloria R., editor.

Series:

Health care in transition series.

Health care in transition

Language:

English

Subjects (All):

Pharmaceutical services insurance--Government policy--United States.

Pharmaceutical services insurance.

Medicare.

Pharmaceutical policy.

Physical Description:

1 online resource (145 p.)

Place of Publication:

New York : Nova Publishers, [2014]

Language Note:

English

Summary:

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (generally referred to as the Medicare Modernization Act, or MMA) substantially expanded the federal Medicare program by creating the prescription drug benefit known as Part D. In fiscal year 2013, Medicare Part D covered 39 million people. The federal government spent 59 billion net of premiums on Part D in that year; after accounting for certain payments from states under the program, the net federal cost was 50 billion, which represented 10 percent of net federal spending for Medicare. This book discusses the cost tr

Contents:

""MEDICARE�S PRESCRIPTION DRUG PROGRAM: COMPETITION ISSUES AND COST TRENDS""; ""MEDICARE�S PRESCRIPTION DRUG PROGRAM: COMPETITION ISSUES AND COST TRENDS""; ""Library of Congress Cataloging-in-Publication Data""; ""CONTENTS""; ""PREFACE""; ""Chapter 1: COMPETITION AND THE COST OF MEDICARE�S PRESCRIPTION DRUG PROGRAM""; ""SUMMARY""; ""SECTION 1. THE FEDERAL BUDGETARY COST OF MEDICARE PART D""; ""SECTION 2. THE COMPETITIVE DESIGN OF MEDICARE PART D""; ""SECTION 3. COMPARING MEDICARE PART D AND MEDICAID FEE FOR SERVICE""

""APPENDIX A. CALCULATING THE FEDERAL GOVERNMENT�S PAYMENTS AND BENEFICIARIES� COST-SHARING AMOUNTS FOR MEDICARE PART D""""APPENDIX B. COMPARING THE USE AND PRICES OF DRUGS IN MEDICARE PART D AND MEDICAID FEE FOR SERVICE""; ""Chapter 2: EFFECTS OF USING GENERIC DRUGS ON MEDICARE�S PRESCRIPTION DRUG SPENDING""; ""SUMMARY""; ""BOX 1. GENERIC DRUGS IN THE U.S. PHARMACEUTICAL MARKETPLACE""; ""BOX 2. HOW COMPETITION FROM GENERIC DRUGS AFFECTS PRICES AND QUANTITIES OF PRESCRIPTION DRUGS""; ""APPENDIX: DESCRIPTION OF DATA USED IN THIS ANALYSIS""

""Chapter 3: SPENDING PATTERNS FOR PRESCRIPTION DRUGS UNDER MEDICARE PART D""""THE MEDICARE PART D PROGRAM""; ""NON-LIS BENEFICIARIES""; ""PART D INSURANCE PLANS AND THE STANDARD BENEFIT""; ""DISTRIBUTION OF SPENDING AMONG NON-LIS BENEFICIARIES""; ""DRIVERS OF HIGHER SPENDING AMONG NON-LIS BENEFICIARIES""; ""THE FEDERAL CONTRIBUTION TO PART D SPENDING FOR NON-LIS BENEFICIARIES""; ""IMPLICATIONS OF RECENT HEALTH CARE LEGISLATION FOR NON-LIS BENEFICIARIES""; ""LIS BENEFICIARIES""; ""THE FEDERAL CONTRIBUTION TO SPENDING FOR LIS BENEFICIARIES""; ""COMPARING NON-LIS AND LIS BENEFICIARIES""

""INDEX""

Notes:

Description based upon print version of record.

Includes bibliographical references and index.

Description based on online resource; title from PDF title page (ebrary, viewed November 10, 2014).

ISBN:

1-63463-153-6

OCLC:

914433370